Daiichi Sankyo has announced a new cancer research alliance with DarwinHealth, which will take advantage of DarwinHealth's proprietary novel cancer target database.
The DarwinHealth database and technology were created to identify critical mechanisms linked to tumour dependencies and maintenance beyond genetic mutations, including information on master regulators of specific tumour subtypes, as well as direct upstream modulators spanning more than 35 tumour types.
“Daiichi Sankyo has allied with DarwinHealth on a new cancer drug research project.“
Under the terms of the new deal, Daiichi Sankyo will gain exclusive access to this database in order to identify potential new targets for cancer drug development, in exchange for an upfront payment and milestone-based fees.
Daiichi Sankyo will receive exclusive access to DarwinHealth's database for a predetermined amount of time, with an option to extend. This could facilitate the creation of a new generation of anticancer therapies designed and owned by Daiichi Sankyo.
Dr Antoine Yver, executive vice-president and global head of oncology research and development at Daiichi Sankyo, said: "This new agreement is a natural next step in expanding our current ongoing translational research collaboration and we look forward to working with DarwinHealth to further science to create meaningful treatments for patients with cancer."
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Pharmaceutical